ReviewClinical rheumatology2022
Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.
Review in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Autoimmune diseases in the era of COVID-19: emerging mechanisms, clinical implications, vaccine considerations, and future directions.The Korean journal of internal medicine · 2026Review
- Qualitative analysis of COVID-19 experiences with testing and vaccination among people with systemic lupus erythematosus in the USA.Clinical rheumatology · 2026Article
- Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After.Biomedicines · 2025Article
- Sex- and gender-related differences in systemic lupus erythematosus: a scoping review.Rheumatology international · 2025Article
- Low vaccination rates and awareness status in patients with rheumatoid arthritis: a nationwide cross-sectional survey study.Rheumatology international · 2025Article
- Late-Induced Autoimmune Disorders Post-COVID-19 Vaccination/Infection: Case Report From Iran.Case reports in medicine · 2025Article
- Article
- Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.Rheumatology international · 2024Article
- COVID-19 in Systemic Lupus Erythematosus patients treated with belimumab: a retrospective clinical study.Immunologic research · 2024Article
- Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey.Rheumatology international · 2024Article
- Successful management of belimumab after obinutuzumab in a patient with systemic lupus erythematosus: a case report with an 18-month follow-up.Frontiers in immunology · 2024Article
- Bibliometric analysis of scientific papers on adverse reactions to COVID-19 vaccines published between 2019 and 2023.Human vaccines & immunotherapeutics · 2023Article
- Observational
- Long noncoding RNA SNHG16 regulates TLR4-mediated autophagy and NETosis formation in alveolar hemorrhage associated with systemic lupus erythematosus.Journal of biomedical science · 2023Article
- The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases.Rheumatology and therapy · 2023Article
- Pediatric Systemic Lupus Erythematous in COVID-19 Era.Viruses · 2023Review
- Case report: Unusual patient with dermatomyositis associated with SARS-CoV-2 infection.Frontiers in neurology · 2023Article
- A Framework to Overcome Challenges in the Management of Infections in Patients with Systemic Lupus Erythematosus.Open access rheumatology : research and reviews · 2023Review
- Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with systemic lupus erythematosus (SLE) form a vulnerable group in terms of the impact of the COVID-19 pandemic on disease management. We conducted this overview by searches through Medline/PubMed, Scopus, and the Directory of Open Access Journals (DOAJ). The prevalence and severity of COVID-19, efficacy of COVID-19 vaccination, impact on the management of SLE, and the attitudes of SLE patients to COVID-19 and vaccination were explored. After screening and due exclusions, 198 studies were included for the final review. Patients with SLE have a greater risk of acquiring COVID-19 (0.6-22%) and related hospitalization (30%), severe disease (13.5%), and death (6.5%) than the general population. Older age, male gender, comorbidities, moderate or high disease activity, and glucocorticoid, rituximab, and cyclophosphamide use are associated with unfavorable outcomes, whereas methotrexate and belimumab use showed no association with outcomes. COVID-19 vaccines are safe in SLE with minimal risk of severe flares (< 2%). Vaccine efficacy is negatively associated with glucocorticoids. The overall attitude of patients towards vaccination is positive (54-90%). The pandemic has negatively affected access to medical care, hospitalizations, procurement of drugs, employment, and the mental health of patients which need to be addressed as part of holistic care in SLE. Key Points • Lupus patients are at a greater risk of acquiring COVID-19, related hospitalization, severe disease, and death than the general population. • COVID-19 vaccines are relatively safe for lupus patients with minimal risk of severe flares. • Lupus patients' attitude towards COVID-19 vaccination is predominantly positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.